Literatur

American College of Radiology (ACR) Standards:
Standard for Diagnosis and Management for invasive breast carcinoma.
1998: www.acr.org/

Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland, Robert Koch-Institut.
Krebs in Deutschland – Häufigkeiten und Trends.
4. überarbeitete, aktualisierte Auflage, Saarbrücken 2004.

Assersohn L, Powles TJ, Ashley S, Nash AG, Neal AJ, Sacks N, Chang J, Querci della RU, Naziri N.
Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy.
Ann Oncol 1999; 10 (12): 1451-1455.

Barth A, Brenner RJ, Giuliano AE.
Current management of ductal carcinoma in situ.
West J Med 1995; 163 (4): 360-366.

Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T.
The ATAC Trialist Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Lancet 2002; 359 (9324): 2131-2139.

Blamey RW, Wilson AR, Patnick J.
ABC of breast diseases: screening for breast cancer.
BMJ 2000; 321 (7262): 689-693.

Breast Cancer Disease Site Group.
Surgical Management of Early-Stage Invasive Breast Cancer.
Practice Guideline Report, Version 2.2003.
www.cancercare.on.ca/pdf/pebc1-1f.pdf
(Recherchedatum: 01.06.2004).

BSCR-17.
NCCN Practice Guidelines in Oncology.
Breast Cancer Screening and Diagnosis. Version 1/2003.
www.breastcarecenteronline.com/pdfs/
breast-screening.pdf
(Recherchedatum: 01.06.2004)

Bundesausschuss der Ärzte und Krankenkassen.
Beschluss einer Änderung der Richtlinien des Bundesausschusses der Ärzte und Krankenkassen über die Früherkennung von Krebserkrankungen vom 1.12.2003.
Dtsch Arztebl 2004; A (6): 289

Bundesministerium für Gesundheit und Soziale Sicherung.
Patientenrechte in Deutschland.
www.bmgs.bund.de/download/broschueren/A407.pdf
(Recherchedatum: 01.06.2004)

Buzdar AU.
Endocrine therapy in the treatment of metastatic breast cancer.
Semin Oncol 2001; 28 (3): 291-304.

Cerwenka H.
Invited commentary to the publication cited before.
Eur Surg 2004; 36: 46-38.

Clark GM, Osborne CK, McGuire WL.
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.
J Clin Oncol 1984; 2 (10): 1102-1109.

Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS.
Progesterone receptors as a prognostic factor in Stage II breast cancer.
N Engl J Med 1983; 309 (22): 1343-1347.

Cross SS.
Immunohistochemical demonstration of oestrogen and progesterone receptors.
J Clin Pathol 2001; 54 (1): 78-79.

Deutsche Krebsgesellschaft und beteiligte medizinisch-wissenschaftliche Fachgesellschaften.
Diagnostik, Therapie und Nachsorge des Mammakarzinoms der Frau – Eine nationale S3-Leitlinie.
AWMF-Leitlinienregister, Nr. 032/045, Entwicklungsstufe 3 + IDA, Juni 2004.
www.uni-duesseldorf.de/awmf/ll/index.html
(Recherchedatum: 01.06.2004).

DiBiase SJ, Komarnicky LT, Heron DE, Schwartz GF, Mansfield CM.
Influence of radiation dose on positive surgical margins in women undergoing breast conservation therapy.
Int J Radiat Oncol Biol Phys 2002; 53 (3): 680-686.

DiBiase SJ, Komarnicky LT, Schwartz GF, Xie Y, Mansfield CM.
The number of positive margins influences the outcome of women treated with breast preservation for early stage breast carcinoma.
Cancer 1998; 82 (11): 2212-2220.

Dowsett M.
Preoperative models to evaluate endocrine strategies for breast cancer.
Clin Cancer Res 2003; 9 (1 Pt 2): 502S-510S.

Early Breast Cancer Trialists’ Collaborative Group.
Tamoxifen for early breast cancer: an overview of the randomised trials.
Lancet 1998; 351 (9114): 1451-1467

Early Breast Cancer Trialists’ Collaborative Group.
Effects of radiotherapy and surgery in early breast cancer – An overview of the Randomized Trials.
N Engl J Med 1995; 333 (22): 1444-1455.

Early Breast Cancer Trialists’ Collaborative Group.
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists’ Collaborative Group.
Lancet 1992; 339 (8784): 1-15, 71-85.

European Commission. European Guidelines for Quality Assurance in Mammography Screening.
Third Edition, European Commission 2001.
europa.eu.int/comm/health/ph/programmes/
cancer/pub/guidelines_toc_en.pdf
(Recherchedatum: 12.05.2004)

Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong J-H, Wolmark N.
Twenty-Year Follow-up of a randomized Trial Comparing Total Mastectomy, Lumectomy, and Lumpectomy plus Irradiation for the Treatment of invasive Breast Cancer.
N Engl J Med 2002; 347 (16): 1233-1241.

Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL.
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
J Natl Cancer Inst 1996; 88 (21): 1529-1542.

Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A.
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
J Clin Oncol 1998; 16 (10): 3439-3460.

Fowble B, Hanlon AL, Fein DA, Hoffman JP, Sigurdson ER, Patchefsky A, Kessler H.
Results of conservative surgery and radiation for mammographically detected ductal carcinoma in situ (DCIS).
Int J Radiat Oncol Biol Phys 1997; 38 (5): 949-957.

German Breast Cancer Study Group (GBSG).
Therapy of small breast cancer-four-year results of a prospective non-randomized study.
Breast Cancer Res Treat 1995; 34 (1): 1-13.

Giersdorf N, Loh A, Härter M, et al.
Messung der partizipativen Entscheidungsfindung.
Z ärztl Fortbild Qual Gesundh wes 2004; 98: 135-141.

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ.
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.
J Clin Oncol 2003; 21 (17): 3357-3365.

Harvey JM, Clark GM, Osborne CK, Allred DC.
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
J Clin Oncol 1999; 17 (5): 1474-1481.

Horwitz KB, McGuire WL.
Specific progesterone receptors in human breast cancer.
Steroids 1975; 25 (4): 497-505.

Irwig L, Bennetts A.
Quality of life after breast cancer conservation or mastectomy: a systematic review.
Aust N Z J Surg 1997; 67: 750-754.

Jensen EV, De Sombre ER, Jungblut PW.
Estrogen receptors in hormone responsive tissues and tumors.
In: Wissler RW, Dao TL, Wood S (Eds.). Endogenous factors influencing host-tumor balance, University of Chicago Press 1967, 15-30

Johnston SRD, Gorbunova L, Evans TRJ, et al.
A multi-double-blind randomised phase III trial of idoxifene versus tamoxifene as first-line endocrine therapy for metastatic breast cancer.
Proc Am Soc Clin Oncol 2001; 29

Jonat W, Maass H.
Steroidhormonrezeptoren im Karzinomgewebe.
Stuttgart: Enke Verlag; 1982

Locker AP, Ellis IO, Morgan DA, Elston CW, Mitchell A, Blamey RW.
Factors influencing local recurrence after excision and radiotherapy for primary breast cancer.
Br J Surg 1989; 76 (9): 890-894.

Maass H, Engel B, Hohmeister H, Lehmann F, Trams G.
Estrogen receptors in human breast cancer tissue.
Am J Obstet Gynecol 1972; 113 (3): 377-382.

McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM.
How to use prognostic factors in axillary node-negative breast cancer patients.
J Natl Cancer Inst 1990; 82 (12): 1006-1015.

Meric F, Mirza NQ, Vlastos G, Buchholz TA, Kuerer HM, Babiera GV, Singletary SE, Ross MI, Ames FC, Feig BW, Krishnamurthy S, Perkins GH, McNeese MD, Strom EA, Valero V, Hunt KK.
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy.
Cancer 2003; 97 (4): 926-933.

Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M.
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
J Clin Oncol 2001; 19 (10): 2596-2606.

Obedian E, Haffty BG.
Negative margin status improves local control in conservatively managed breast cancer patients.
Cancer J Sci Am 2000; 6 (1): 28-33.

Park CC, Mitsumori M, Nixon A, Recht A, Connolly J, Gelman R, Silver B, Hetelekidis S, Abner A, Harris JR, Schnitt SJ.
Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence.
J Clin Oncol 2000; 18 (8): 1668-1675.

Perry NM.
Quality assurance in the diagnosis of breast
disease. EUSOMA Working Party.
Eur J Cancer 2001; 37 (2): 159-172.

Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, Menard C, Lippman ME, Lichter AS, Altemus RM.
Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.
Cancer 2003; 98 (4): 697-702.

Remmele W, Stegner HE.
Vorschlag zur einheitlichen Definition eines Immunreaktiven Score (IRS) für den Immunhistochemischen Östrogenrezeptor-Nachweis (ER-ICA) im Mammmakarzinomgewebe.
Pathologe 1987; 8 (3): 138-140.

Rhodes A, Jasani B, Balaton AJ, Miller KD.
Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries.
J Clin Pathol 2000a; 53 (4): 292-301.

Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD.
Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening.
J Clin Pathol 2000b; 53 (9): 688-696.

Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD.
Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems.
J Clin Pathol 2000c; 53 (2): 125-130.

Sachverständigenrat für die Konzertierte Aktion im Gesundheitswesen.
Bedarfsgerechtigkeit und Wirtschaftlichkeit: Band III Über-, Unter- und Fehlversorgung Gutachten 2000/2001.

Saez S, Cheix F, Asselain B.
Prognostic value of estrogen and progesterone receptors in primary breast cancer.
Breast Cancer Res Treat 1983; 3 (4): 345-353.

Scarth H, Cantin J, Levine M,
for the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
Clinical Practice Guidelines for the Care and Treatment of Breast Cancer: 3. Mastectomy or lumpectomy? The choice of operation for clinical stages I and II breast cancer (2002 update).
www.cmaj.ca/cgi/content/ full/167/2/154
(Recherchedatum: 15.06.2004)

Schulz KD, Albert US, Mitglieder der Planungsgruppe und Leiter der Arbeitsgruppen
Konzertierte Aktion Brustkrebs-Früherkennung in Deutschland. Stufe-3-Leitlinie „Brustkrebsfrüherkennung in Deutschland“.
München: W. Zuckschwerdt Verlag; 2003

Sibbering DM, Galea MH, Morgan DAL, Elston CW, Ellis IO, Robertson JFR, Blamey RW.
Safe Selection Criteria for Breast Conservation Without Radical Excision in Primary Operable Invasive Breast Cancer.
Eur J Cancer 1995; 31A (13/14): 2191-2195.

Silverstein MJ.
Ductal carcinoma in situ of the breast.
Philadelphia: Lippincott Williams; 2002

Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, Gamagami P, Colburn WJ.
The influence of margin width on local control of ductal carcinoma in situ of the breast.
N Engl J Med 1999; 340 (19): 1455-1461.

Ständige Kongresskommission „Deutscher Kongress für Versorgungsforschung“.
Memorandum zur Versorgungsforschung in Deutschland.
Frauenarzt 2004 ; 45 (5): 412-414.

Stockler M, Wilcken NR, Ghersi D, Simes RJ.
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer.
Cancer Treat Rev 2000; 26 (3): 151-168.

Taucher S, Rudas M, Gnant M, Dubsky P, Sporn E, Roka S, Bachleitner T, Fitzal F, Kandioler D, Wenzel C, Steger G, Draxler W, Mittlböck M, Jakesz R.
The impact of progesterone receptor in prediction of complete pathological response to preoperative chemotherapy in primary breast cancer patients.
Eur Surg 2004; 36: 41-45.

Tyldesley S, Foroudi F, Barbera L, Boyd C, Schulze K, Walker H, Mackillop WJ.
The appropriate rate of breast conserving surgery: an evidence-based estimate.
Clin Oncol (R Coll Radiol ) 2003; 15 (3): 144-155.

Veronesi U, Banfi A, Salvadori B, Luini A, Saccozzi R, Zucali R, Marubini E, Del Vecchio M, Boracchi P, Marchini S.
Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial.
Eur J Cancer 1990a; 26 (6): 668-670.

Veronesi U, Salvadori B, Luini A, Banfi A, Zucali R, Del Vecchio M, Saccozzi R, Beretta E, Boracchi P, Farante G,
Conservative treatment of early breast cancer. Long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy.
Ann Surg 1990b; 211 (3): 250-259.

Veronesi U, Volterrani F, Luini A, Saccozzi R, Del Vecchio M, Zucali R, Galimberti V, Rasponi A, Di Re E, Squicciarini P.
Quadrantectomy versus lumpectomy for small size breast cancer.
Eur J Cancer 1990c; 26 (6): 671-673.

Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E.
Twenty-Year Follow-up of a Randomized Study comparing Breast-Consering Surgery with Radical Mastectomy for Early Breast Cancer.
N Engl J Med 2002; 347 (16): 1227-1232.

Vodermaier A, Caspari C, Köhm J, Bauerfeind I, Kahlert S, Untch M.
Partizipative Entscheidungsfindung beim primären Mammakarzinom.
Z ärztl Fortbild Qual Gesundh wes 2004; 98: 127-133.

Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM, McGuire WL.
DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients.
Breast Cancer Res Treat 1993; 28 (1): 9-20.